CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on creating and providing treatments for liver and various other chronic conditions. Its leading investigational drug is seladelpar (MBX-8025), a selective agonist for the peroxisome proliferator activated receptor delta, which is presently in a Phase III clinical trial for primary biliary cholangitis (PBC). This compound has also successfully completed a Phase 2b clinical study for patients suffering from nonalcoholic steatohepatitis (NASH).